Early switch from run-in with targeted to immunotherapy in advanced BRAF(V600)-positive melanoma: final results of the randomised phase II ImmunoCobiVem trial.

Livingstone E, Gogas HJ, Kandolf L, Meier F, Eigentler TK, Ziemer M, Terheyden P, Gesierich A, Herbst RA, Kähler KC, Ziogas DC, Mijušković Ž, Garzarolli M, Garbe C, Roesch A, Ugurel S, Gutzmer R, Gaudy-Marqueste C, Kiecker F, Utikal J, Hartmann M, Miethe S, Eckhardt S, Zimmer L, Schadendorf D

Open source

DOI: 10.1016/j.esmoop.2025.105053
Published: 2025 May
Container: ESMO open
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.esmoop.2025.105053,
  title = {Early switch from run-in with targeted to immunotherapy in advanced BRAF(V600)-positive melanoma: final results of the randomised phase II ImmunoCobiVem trial.},
  author = {Livingstone E and Gogas HJ and Kandolf L and Meier F and Eigentler TK and Ziemer M and Terheyden P and Gesierich A and Herbst RA and Kähler KC and Ziogas DC and Mijušković Ž and Garzarolli M and Garbe C and Roesch A and Ugurel S and Gutzmer R and Gaudy-Marqueste C and Kiecker F and Utikal J and Hartmann M and Miethe S and Eckhardt S and Zimmer L and Schadendorf D},
  year = {2025},
  journal = {ESMO open},
  doi = {10.1016/j.esmoop.2025.105053},
  url = {https://doi.org/10.1016/j.esmoop.2025.105053}
}

RIS

TY  - JOUR
TI  - Early switch from run-in with targeted to immunotherapy in advanced BRAF(V600)-positive melanoma: final results of the randomised phase II ImmunoCobiVem trial.
AU  - Livingstone E
AU  - Gogas HJ
AU  - Kandolf L
AU  - Meier F
AU  - Eigentler TK
AU  - Ziemer M
AU  - Terheyden P
AU  - Gesierich A
AU  - Herbst RA
AU  - Kähler KC
AU  - Ziogas DC
AU  - Mijušković Ž
AU  - Garzarolli M
AU  - Garbe C
AU  - Roesch A
AU  - Ugurel S
AU  - Gutzmer R
AU  - Gaudy-Marqueste C
AU  - Kiecker F
AU  - Utikal J
AU  - Hartmann M
AU  - Miethe S
AU  - Eckhardt S
AU  - Zimmer L
AU  - Schadendorf D
PY  - 2025
JO  - ESMO open
DO  - 10.1016/j.esmoop.2025.105053
UR  - https://doi.org/10.1016/j.esmoop.2025.105053
ER  -

APA

E, L., HJ, G., L, K., F, M., TK, E., M, Z., P, T., A, G., RA, H., KC, K., DC, Z., Ž, M., M, G., C, G., A, R., S, U., R, G., C, G., F, K., J, U., M, H., S, M., S, E., L, Z., & D, S. (2025). Early switch from run-in with targeted to immunotherapy in advanced BRAF(V600)-positive melanoma: final results of the randomised phase II ImmunoCobiVem trial.. ESMO open. https://doi.org/10.1016/j.esmoop.2025.105053

Source records

pubmed · retrieved 2026-09-25T17:18:21.061Z